- Home
- CTV vs CRBU Comparison
CTV vs CRBU Comparison
Compare CTV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTV
- CRBU
- Stock Information
- Founded
- CTV 2007
- CRBU 2011
- Country
- CTV United States
- CRBU United States
- Employees
- CTV N/A
- CRBU N/A
- Industry
- CTV Advertising
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- CTV Consumer Discretionary
- CRBU Health Care
- Exchange
- CTV Nasdaq
- CRBU Nasdaq
- Market Cap
- CTV 279.6M
- CRBU 236.3M
- IPO Year
- CTV N/A
- CRBU 2021
- Fundamental
- Price
- CTV $3.07
- CRBU $1.87
- Analyst Decision
- CTV Hold
- CRBU Strong Buy
- Analyst Count
- CTV 3
- CRBU 4
- Target Price
- CTV $2.83
- CRBU $12.00
- AVG Volume (30 Days)
- CTV 5.4M
- CRBU 1.5M
- Earning Date
- CTV 11-12-2024
- CRBU 11-06-2024
- Dividend Yield
- CTV N/A
- CRBU N/A
- EPS Growth
- CTV N/A
- CRBU N/A
- EPS
- CTV N/A
- CRBU N/A
- Revenue
- CTV $151,557,000.00
- CRBU $11,475,000.00
- Revenue This Year
- CTV $9.64
- CRBU N/A
- Revenue Next Year
- CTV $10.07
- CRBU N/A
- P/E Ratio
- CTV N/A
- CRBU N/A
- Revenue Growth
- CTV 12.30
- CRBU N/A
- 52 Week Low
- CTV $1.25
- CRBU $1.50
- 52 Week High
- CTV $3.09
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- CTV 78.42
- CRBU 41.82
- Support Level
- CTV $3.05
- CRBU $1.82
- Resistance Level
- CTV $3.09
- CRBU $1.97
- Average True Range (ATR)
- CTV 0.02
- CRBU 0.14
- MACD
- CTV -0.03
- CRBU -0.02
- Stochastic Oscillator
- CTV 65.17
- CRBU 14.29
About CTV Innovid Corp.
Innovid Corp is a software platform that provides ad serving, measurement and optimization creative services for the creation, delivery, and measurement of TV ads across connected TV, mobile TV and desktop TV environments to advertisers, publishers and media agencies. It is engaged in ad serving, measurement and creative services. It operates in U.S., Canada, EMEA, APAC and LATAM, out of which it derives maximum revenue from U.S.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.